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Abstract
Accumulating evidence indicates that increased generation of reactive oxygen species (ROS) contributes to the development
of exaggerated pain hypersensitivity during persistent pain. In the present study, we investigated the antinociceptive efficacy
of the antioxidants vitamin C and vitamin E in mouse models of inflammatory and neuropathic pain. We show that systemic
administration of a combination of vitamins C and E inhibited the early behavioral responses to formalin injection and the
neuropathic pain behavior after peripheral nerve injury, but not the inflammatory pain behavior induced by Complete
Freund’s Adjuvant. In contrast, vitamin C or vitamin E given alone failed to affect the nociceptive behavior in all tested models.
The attenuated neuropathic pain behavior induced by the vitamin C and E combination was paralleled by a reduced p38
phosphorylation in the spinal cord and in dorsal root ganglia, and was also observed after intrathecal injection of the vitamins.
Moreover, the vitamin C and E combination ameliorated the allodynia induced by an intrathecally delivered ROS donor. Our
results suggest that administration of vitamins C and E in combination may exert synergistic antinociceptive effects, and
further indicate that ROS essentially contribute to nociceptive processing in special pain states.
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Introduction
Reactive oxygen species (ROS), such as superoxide, hydrogen
peroxide and hydroxyl radicals, are derived from the metabolism
of molecular oxygen [1,2]. Due to their highly reactive nature,
ROS can damage nucleic acids, proteins and lipids, especially at
high concentrations. Accordingly, excessive production of ROS in
the central nervous system (CNS) contributes to the pathogenesis
of many neurodegenerative diseases including Alzheimer’s disease,
Parkinson’s disease and amyotrophic lateral sclerosis [3]. Recent
studies suggest that ROS at physiological concentrations can
mediate reversible regulatory processes and serve as functional
messenger molecules, possibly fulfilling a large range of physiologic
and pathophysiologic functions [4]. Notably, accumulating
evidence indicates that ROS are involved in the sensitization of
pain pathways during persistent pain. For example, an increased
ROS production has been detected in the spinal cord and in
peripheral tissues after noxious hindpaw stimulation or nerve
injury [5–7]. Mice lacking the superoxide-generating NADPH
oxidases Nox1 or Nox2 demonstrated a reduced nociceptive
behavior in animal models of inflammatory or neuropathic pain,
respectively, indicating a contribution of NADPH oxidase-
mediated superoxide production to pain sensitization [8,9].
Moreover, inflammatory and neuropathic pain was effectively
inhibited in animal models after administration of free radical
scavengers or superoxide dismutase mimetics [10–14], further
suggesting that ROS contribute to nociceptive processing.
Vitamin C (Vit C) and vitamin E (Vit E) are essential nutrients
that function as antioxidants in the human body. Vit C (L-ascorbic
acid) is a water-soluble sugar acid that exists at physiological pH as
a monovalent anion, ascorbate, which is capable to scavenge ROS
[15]. Vit E (alpha-tocopherol), a fat-soluble vitamin, is the major
chain-breaking antioxidant in body tissues and is the first line of
defense against lipid peroxidation, protecting cell membranes from
free radical attack [16]. Notably, Vit C is able to recycle Vit E by
reduction of the tocopheroxyl radical of Vit E, thereby permitting
Vit E to function again as a free radical chain-breaking antioxidant
[17]. Based on the observation that (i) ROS contribute to
nociceptive signaling and that (ii) the natural compounds Vit C
and Vit E may exert additive antioxidant effects, we hypothesized
that a combination of both vitamins might attenuate persistent
pain. Hence, the goal of this study was to evaluate whether or not
exogenous Vit C and Vit E are able to inhibit nociceptive behavior
in animal models of inflammatory or neuropathic pain.
Methods
Ethics Statement
All experiments were approved by the federal authority for
animal research (Regierungspra ¨sidium Darmstadt, Hessen, Ger-
many) and were carried out in strict accordance with the National
Institutes of Health’s Guide for the Care and Use of Laboratory
Animals. All efforts were made to minimize suffering.
Animals
Male C57BL/6 mice (8–9 weeks old, 2561 g) were obtained
from Harlan Laboratories. Animals were maintained under a 12/
12-h light/dark cycle with free access to water and standard chow
(ssniffH R/M-H; ssniff, Soest, Germany).
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Commercially available liquid parenteral formulations of Vit C
(PascorbinH, Pascoe, Giessen, Germany and Vitamin C-Rotexme-
dicaH, Rotexmedica, Trittau, Germany; containing 150 and
100 mg/ml L-ascorbic acid, respectively) and Vit E (Vitamin E
SanumH, Sanum-Kehlbeck, Hoya, Germany and EphynalH,
Bayer, Barcelona, Spain; containing 75 and 50 mg/ml alpha-
tocopherol acetate, respectively), or 0.9% saline (B. Braun,
Melsungen, Germany) were used. For multiple daily intraperito-
neal (i.p.) injections and oral administrations of low vitamin doses,
the vitamin formulations were diluted with 0.9% saline. For
intrathecal (i.t.) injections (injection volume 2.5 ml), L-ascorbic acid
(Sigma-Aldrich, Munich, Germany) was added to the Vit C
formulation (PascorbinH) to obtain a final concentration of
300 mg/ml and NaHCO3 was used to adjust pH to 7.0, whereas
alpha-tocopherol acetate (Sigma-Aldrich) was added to the Vit E
formulation (Vitamin E SanumH) to obtain a final concentration of
150 mg/ml. Vitamins C and E in combination were administered
by consecutive single doses of Vit C and Vit E, respectively. All
drug preparations were performed immediately before adminis-
tration to minimize air oxidation of the vitamin solutions.
Behavioral Testing
Prior to behavioral testing, animals were habituated to the
experimental room for at least 1 h. Experiments were performed
by an observer blinded for the treatment of the animals.
Formalin test. Twenty or two minutes after i.p. drug
injection, 15 ml of a 5% formaldehyde solution (formalin) was
injected subcutaneously into the dorsal surface of a hindpaw
[18,19]. The time spent licking the formalin-injected paw was
recorded in 5 min intervals up to 60 min after formalin injection.
Dynamic-plantar test. The mechanical sensitivity of the
plantar side of a hindpaw was assessed with an automated von
Frey-type testing device (Dynamic Plantar Aesthesiometer, Ugo
Basile) which allows for reliable detection of mechanical sensitivity
in mice [20–23]. The stainless steel probe of the touch stimulator
unit was pushed against the paw with ascending force until a
strong and immediate withdrawal occurred. The maximum force
was set at 5 g and the ramp speed was 0.5 g/s. The paw
withdrawal latency was calculated as the mean of five to six
consecutive trials with at least 20 s in between.
CFA-induced mechanical hyperalgesia. Twenty microliter
of complete Freund’s adjuvant (CFA, containing 1 mg/ml of heat
killed Mycobacterium tuberculosis in paraffin oil 85% and mannide
monooleate 15%, Sigma-Aldrich) were injected into the plantar
subcutaneous space of a hindpaw [24]. Twenty-four hours after
CFA injection, hindpaw withdrawal latencies were determined
using the dynamic plantar test to confirm CFA-induced
mechanical hyperalgesia. Thereafter drugs were i.p. injected,
and hindpaw withdrawal latencies were determined at 1, 2, 4, 6,
24 h after drug injection. Immediately after the 24 h measurement
(i.e., 48 h after CFA), animals received a second i.p. injection of
the same drug, and hindpaw withdrawal latencies were again
determined at 1, 2, 4, 6, 24 h thereafter. For investigation of long-
term effects with multiple daily injections, drugs were i.p.
administered once a day starting 30 min after CFA injection,
and withdrawal latencies were investigated 1 h after drug
injections at 1, 3, 5, 7, 10 and 12 d after CFA injection.
SNI-induced neuropathic pain. The ‘spared nerve injury’
(SNI) model was used to investigate neuropathic pain. Under
general anesthesia (1.5% isoflurane), the tibial and common
peroneal branches of the sciatic nerve were ligated and sectioned
distally, while the sural nerve was left intact [25]. Mechanical
allodynia was determined using the dynamic-plantar test. For
investigation of immediate effects of drug injections, drugs were i.p.
or intrathecally (i.t.) administered 15 days after SNI surgery and
paw withdrawal latencies were determined at 1, 2, 4, 6, 24 h after
drug injection. Immediately after the 24 h measurement, drugs
were again administered and withdrawal latencies were determined
at 1, 2, 4, 6, 24 h thereafter. For investigation of long-term effects
with multiple daily dosing, drugs were administered once a day
starting 30 min after SNI surgery, and withdrawal latencies were
investigated at3,6,8,10and12 d afterSNI surgery.Measurements
were performed 1 h after i.p. administration, or 1 and 2 h after oral
administration (by gavage). For the latter, the mean of both
measurements was calculated.
Intrathecal injections. For i.t. delivery, drugs were injected
by direct lumbar puncture in awake, conscious mice as described
[26]. Briefly, a 10 ml Hamilton syringe connected to a 30 gauge,
0.5 inch needle was inserted in a 70–80u angle at the midline
between the hip bones (held by the thumb and forefinger of the
experimenter). After contact with the bone of the spinal column
was sensed, the needle angle was reduced to approximately 30u
and slipped in between the vertebrae. Drugs were i.t. injected in a
volume of 2.5 ml immediately after a reflexive tail flick or`S`shape
indicating puncture of the dura mater. An accuracy .95% was
achieved by dye injections in training sessions prior to the
experiment.
TBHP-induced allodynia. One hour after i.p. drug injection,
100 mg TBHP (tert-butyl hydroperoxide; Sigma Aldrich) dissolved
in 5 ml saline was i.t. injected as described above. Mechanical
allodynia was determined using the dynamic-plantar test.
Western Blot Analysis
Mice were i.p. injected with Vit C and Vit E or 0.9% saline 14
and 15 days after SNI surgery. Three hours after the second drug
injection, mice were killed by carbon dioxide, the lumbar spinal
cord and dorsal root ganglia (DRGs, L3–L5) were rapidly
dissected, immediately frozen in liquid nitrogen and stored at
280uC until use. Tissue samples were homogenized in Phospho-
safe extraction reagent (Novagen, Madison, WI) mixed with a
protease inhibitor cocktail (Complete Mini; Roche Diagnostics,
Mannheim, Germany), and centrifuged at 14,0006 g for 1 h.
Extracted proteins (20 mg per lane) were separated by SDS-
polyacrylamide gel electrophoresis and transferred onto nitrocel-
lulose membranes by electroblotting. After incubating in blocking
buffer (Odyssey blocking buffer; LI-COR Biosciences, Bad
Homburg, Germany; diluted 1:1 with PBS) for 1 h, membranes
were incubated overnight at 4uC with antibodies directed against
phopho-p38 mitogen-activated protein kinase (MAPK) (Thr180/
Tyr182; 1:100; Cell Signaling, Danvers, MA), p38 MAPK (1:100;
Cell Signaling), phospho-p44/42 MAPK (Thr202/Tyr204; 1:100;
Cell Signaling), p44/42 MAPK (1:500; Promega, Madison, WI) or
calnexin (1:100; Santa Cruz Biotechnology, Santa Cruz, CA)
diluted in blocking buffer containing 0.2% Tween. After
incubation with the secondary antibodies conjugated with Alexa
Fluor 680 or 800 (1:10000; Invitrogen, Carlsbad, CA) for 2 h,
blots were visualized on a Odyssey Infrared Imaging System (LI-
COR Biosciences). Band densities were quantified by densitometry
using the ImageJ 1.43 software (NIH, USA). Data are given in
relation to the individual calnexin loading control and are
normalized to band intensities of spinal cord extracts of saline-
treated animals.
Statistics
Statistical evaluation was done with SPSS 17.0 for Windows
(SPSS, Chicago, IL). The Kolmogorov-Smirnov test was used to
assess normal distribution of data within groups. Data were
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by Fisher post hoc test. For all tests, a probability value P,0.05 was
considered as statistically significant. All data are expressed as the
mean 6 SEM, and the error bars represent SEM.
Results
A combination of vitamins C and E inhibits the first phase
of formalin-induced pain behavior
We first assessed whether i.p. injection of Vit C, Vit E or a
combination of both vitamins (Vit C+E) affects the nociceptive
behavior of mice in three well-characterized models of persistent
pain, i.e. the formalin test [18,19], the Complete Freund’s
Adjuvant (CFA)-induced inflammatory hypersensitivity [24] and
the spared nerve injury (SNI)-induced neuropathic hypersensitivity
[25]. Based on studies in rats [27–29] we used doses of 15 mg Vit
C (corresponding to 0.6 g/kg) and 7.5 mg Vit E (corresponding to
0.3 g/kg) for initial screening. In the formalin test, Vit C, Vit E,
Vit C+E or saline were i.p. administered 20 min prior to 5%
formalin injection into a hindpaw, and the nociceptive behavior
was observed over 60 min. The formalin injection evoked the
typical biphasic paw licking behavior. Interestingly, pretreatment
with the Vit C+E combination, but not with Vit C or Vit E alone,
significantly inhibited the first phase of paw licking (1–10 min),
which results from peripheral activation of primary afferents
(Fig. 1). In contrast, the second phase of paw licking (11–60 min)
that involves a period of sensitization was not affected by the
vitamin combination, nor by Vit C or Vit E given alone (Fig. 1).
To exclude the possibility that the selective inhibition of phase 1
but not of phase 2 is due to a short duration of action of the
vitamins, we also tested the effect of the Vit C+E combination
when i.p. administered 2 min prior to formalin injection.
Similarly, pretreatment with Vit C+E 2 min prior to formalin
selectively inhibited the first but not the second phase of paw
licking (data not shown). These data indicate that the combination
of vitamins C and E may inhibit formalin-induced peripheral pain
processing.
Vitamins C and E treatment does not inhibit CFA-induced
pain behavior
We then tested the effect of Vit C and/or Vit E treatment in the
Complete Freund’s Adjuvant (CFA) model of inflammatory pain.
As expected, injection of CFA into a hindpaw evoked mechanical
hyperalgesia, indicated by a drop of paw withdrawal latency times
from 7.860.2 sec before CFA injection to 5.060.1 sec 24 h after
CFA injection (P,0.001). Two doses of Vit C (15 mg), Vit E
(7.5 mg), Vit C+E (15 mg + 7.5 mg) or saline were i.p.
administered, the first dose 24 h and the second dose 48 h after
CFA injection. As shown in Fig. 2, the CFA-induced mechanical
hyperalgesia was not affected by Vit C, Vit E or Vit C+E. In
contrast, the hyperalgesia was significantly reduced after admin-
istration of diclofenac (10 mg/kg i.p.) that was used as a positive
control (data not shown). Hence, CFA-induced inflammatory
hyperalgesia, in contrast to formalin-induced paw licking, is
obviously not inhibited by Vit C+E treatment in the doses given.
A combination of vitamins C and E attenuates
SNI-induced neuropathic pain behavior
We then analyzed the effect of Vit C and/or E treatment in the
SNI model of neuropathic pain. Fourteen days after SNI surgery,
paw withdrawal latency times in the SNI-operated hindpaw were
4.460.1 sec as compared to 8.360.3 sec before SNI surgery
(P,0.001), indicating mechanical allodynia. Interestingly, i.p.
administration of Vit C+E (15 mg + 7.5 mg, respectively)
significantly alleviated the mechanical allodynia 1 h after drug
injection (Fig. 3A). Moreover, a sustained effect was observed
when a second injection of Vit C+E was given 24 h after the first
injection. By contrast, administration of Vit C or Vit E alone did
not affect mechanical allodynia (Fig. 3A). These data indicate that
coadministration of vitamins C and E may inhibit SNI-induced
neuropathic pain behavior.
In order to investigate whether the antinociceptive effect of Vit
C+E is dose-dependent, we administered twofold higher doses of
the vitamins (i.e., 30 mg Vit C and/or 15 mg Vit E) 14 and 15 d
after SNI surgery. As shown in Fig. 3B, higher doses of the vitamin
combination alleviated the neuropathic pain behavior more
effectively than lower doses (compare to Fig. 3A), and stronger
effects were again observed after the second drug injection which
was given 24 h after the first injection. By contrast, administration
of 30 mg Vit C or 15 mg Vit E alone did not affect mechanical
hypersensitivity (Fig. 3B). Thus, SNI-induced neuropathic pain
behavior was dose-dependently inhibited by systemic administra-
tion of a combination of vitamins C and E, but not by
administration of Vit C or Vit E alone.
Figure 1. Antinociceptive effects of a Vit C and Vit E
combination in the formalin test. Drugs (15 mg Vit C, 7.5 mg Vit
E, the combination of 15 mg Vit C and 7.5 mg Vit E, or saline) were
intraperitoneally administered 20 min prior to injection of formalin
(15 ml, 5%) into a hindpaw. Sum of paw-licking time in phase 1 (1–
10 min) and phase 2 (11–60 min). Note that the licking behavior in
phase 1 is considerably reduced in mice treated with the Vit C+E
combination. n=6–8 per group; *significantly different from saline
group, p,0.05.
doi:10.1371/journal.pone.0029240.g001
Figure 2. CFA-induced inflammatory pain behavior is not
affected by Vit C and Vit E treatment. Mice were injected with
20 ml CFA into a hindpaw. Drugs (15 mg Vit C, 7.5 mg Vit E, the
combination of 15 mg Vit C and 7.5 mg Vit E, or saline) were i.p.
administered 24 h (time point ‘0’) and 48 h (time point ‘24’) after CFA
injection. Paw withdrawal latency times upon mechanical stimulation
are expressed as difference to baseline (i.e. prior to the first drug
injection). Statistical analyses revealed no significant differences
between groups. n=7–8 per group.
doi:10.1371/journal.pone.0029240.g002
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attenuates SNI-induced neuropathic pain behavior
The i.p. administered combination of vitamins C and E may act
on multiple sites of the nociceptive system. To determine the
importance of the spinal cord as an active site for the attenuation
of neuropathic pain behavior, we analyzed the effect of intrathecal
(i.t.) administration of Vit C and/or Vit E on SNI-induced
mechanical allodynia. Vit C (0.75 mg) and Vit E (0.375 mg) or Vit
C+E (0.75 + 0.375 mg), corresponding to 5% of the effective
systemic doses, were i.t. injected 14 and 15 days after SNI surgery.
Interestingly, the vitamin combination significantly reduced
mechanical allodynia over 2–6 h after the first and over 2–24 h
after the second i.t. injection, respectively (Fig. 4). Vit E given
alone significantly reduced allodynia 24 h after the second i.t.
injection, whereas Vit C given alone was without effect (Fig. 4).
These data point to the spinal cord as an action site for the
antinociceptive effects of the Vit C+E combination during
neuropathic pain.
Vitamins C and E in combination inhibit p38 MAPK
phosphorylation in the spinal cord and in DRGs
Because MAP kinase activation is an important contributor to
central sensitization during nociceptive processing [30] and MAP
kinases have been suggested as a downstream signaling mechanism
of ROS in other tissues [31], we investigated the effect of Vit C+E
treatment on p38 and ERK (p42 and p44) MAPK activation in the
spinal cord and DRGs by western blot analyses. Fourteen and 15
days after SNI surgery mice were i.p. injected with the Vit C+E
combination or saline, and tissues were excised 3 h after the
second drug injection, i.e. at a time point of antinociceptive effects
of Vit C+E (compare to Fig. 3B). Interestingly, in Vit C+E treated
mice we observed significant decreased phospho-p38 protein levels
in the spinal cord and in DRGs (P=0.002 and 0.022, respectively)
as compared to saline treated mice (Fig. 5A). Furthermore, a trend
of decreased p44 phosphorylation was detected in DRGs of Vit
C+E treated mice (Fig. 5B), which was however not significant
(P=0.137), whereas p42 phosphorylation was not affected. Total
p38, p42 or p44 protein in the spinal cord and DRGs did not
change after Vit C+E treatment. These data suggest that the
antinociceptive effects of Vit C+E on SNI-induced neuropathic
pain behavior might involve an inhibition of p38 activation in the
spinal cord and in DRGs.
Allodynia induced by intrathecal administration of a ROS
donor is attenuated by vitamins C and E in combination
We then assessed whether the Vit C+E combination inhibits
mechanical allodynia induced by i.t. delivery of a ROS donor
[14]. Naive mice were i.p. pretreated with a combination of 30 mg
Vit C and 15 mg Vit E or saline, and the ROS donor TBHP (tert-
butyl hydroperoxide; 100 mg) was i.t. injected 60 min thereafter to
induce mechanical allodynia. As shown in Fig. 6, i.t. TBHP
evoked transient mechanical allodynia in both groups. However,
in mice pretreated with Vit C+E, the TBHP-induced allodynia
was significantly attenuated as compared to control mice
pretreated with saline (Fig. 6). These data suggest that systemic
administration of Vit C and E in combination may inhibit ROS-
induced central sensitization.
Multiple daily administrations of low-dose vitamins C and
E in combination inhibit SNI-induced neuropathic pain
behavior
We next investigated whether Vit C+E at low doses near the
human long-term tolerable upper intake level may also reduce the
neuropathic pain behavior. For this purpose, mice underwent SNI
surgery and were i.p. treated with a combination of low dose Vit
C+E or with saline 30 min after SNI surgery, followed by once-
daily i.p. administration for 12 days. Interestingly, a combination
of 3 mg Vit C + 1.5 mg Vit E significantly inhibited SNI-induced
mechanical allodynia during 6–12 days after SNI surgery (Fig. 7A).
Moreover, in mice treated with 0.75 mg Vit C + 0.375 mg Vit E
mechanical allodynia was gradually attenuated from 8–12 days
Figure 3. A combination of Vit C and Vit E inhibits SNI-induced
neuropathic pain behavior. Mice were subjected to SNI surgery and
drugs (Vit C, Vit E, the combination of Vit C and Vit E, or saline) were i.p.
administered at the indicated doses 14 days (time point ‘0’) and 15 days
(time point ‘24’) after SNI surgery. Paw withdrawal latency times upon
mechanical stimulation are expressed as difference to baseline (i.e. prior
to the first drug injection). Note that the Vit C+E combination dose-
dependently inhibited SNI-induced mechanical allodynia, and that a
sustained effect occurred after a second injection of Vit C+E. n=8 per
group; *significantly different from saline group, p,0.05.
doi:10.1371/journal.pone.0029240.g003
Figure 4. Intrathecally administered Vit C and E inhibit SNI-
induced neuropathic pain behavior. Same experimental setting as
described in Figure 3, but with intrathecal drug administration at the
indicated doses. The Vit C+E combination effectively inhibited SNI-
induced mechanical allodynia after i.t. administration. n=6–8 per
group; *,
#significantly different from saline group (p,0.05) for Vit C+E
and Vit E alone, respectively.
doi:10.1371/journal.pone.0029240.g004
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indicating that antinociceptive effects can be achieved by delivery
of low doses of Vit C+E.
We further analyzed whether antinociceptive effects also occur
after oral administration of the vitamin combination. Mice were
treated by oral gavage with low doses of Vit C+E or with saline
30 min after SNI surgery, followed by once-daily oral adminis-
tration for 12 days. As shown in Fig. 7B, the SNI-induced
mechanical allodynia was also attenuated after oral dosing of the
vitamins. Significant effects were observed after administration of
3 mg Vit C + 1.5 mg Vit E, and of 0.75 mg Vit C + 0.375 mg Vit
E, respectively (Fig. 7B). Hence, multiple daily i.p. or oral
administrations of low doses of Vitamins C and E in combination
may inhibit SNI-induced neuropathic pain behavior.
Multiple daily administrations of low-dose vitamins C and
E in combination do not inhibit CFA-induced
inflammatory pain behavior
Finally, we investigated whether Vit C+E at low doses may
reduce the CFA-induced inflammatory pain behavior. CFA was
injected into a hindpaw and mice were i.p. treated with a
combination of low dose Vit C+E (0.75 mg Vit C + 0.375 mg Vit
E; and 3 mg Vit C + 1.5 mg Vit E) or with saline 30 min after
CFA injection, followed by once-daily administration for 12 days.
The CFA injection evoked transient mechanical hyperalgesia in all
groups (Fig. 8). In contrast to the neuropathic pain behavior, the
inflammatory pain behavior was not inhibited by daily low-dose
Vit C+E treatment (Fig. 8). These data are in parallel with our
observation that two injections of high-dose Vit C+E do not affect
CFA-induced inflammatory pain behavior (Fig. 2). All together,
we conclude that vitamins C and E in combination may inhibit
nociceptive processing in special pain states.
Figure 5. Vit C and Vit E treatment attenuates phosphorylation of p38, but not of p42 or p44, in the spinal cord and DRGs. Mice were
subjected to SNI surgery and received two i.p. injections of saline or the combination of Vit C (30 mg) and Vit E (15 mg) at days 14 and 15 after SNI.
The protein expression of phospho-p38 (p-p38) and p-38 (A), and of phospho-p42 (p-p42), p42, phospho-p44 (p-p44) and p44 (B) in the spinal cord
and DRGs was analyzed by western blotting of tissues obtained 3 h after the second drug injection. Calnexin was used as loading control.
Representative western blots are shown on the left, densitometric analyses are shown on the right. n=3 animals per group; *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0029240.g005
Figure 6. Vit C and Vit E pretreatment attenuates mechanical
allodynia induced by intrathecal TBHP. Mice were i.p. pretreated
with a combination of 30 mg Vit C and 15 mg Vit E or saline. One hour
thereafter, the ROS donor TBHP (100 mg) was i.t. injected (time point
‘0’), and paw withdrawal latency times upon mechanical stimulation
were measured for 105 min. n=6 per group; *significantly different
from saline group, p,0.05.
doi:10.1371/journal.pone.0029240.g006
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In the present study, we show that a combination of vitamins C
and E inhibits the nociceptive behavior of mice. Systemically
administered Vit C+E, in contrast to Vit C or Vit E alone,
attenuated the nociceptive behavior in the formalin test (phase 1)
and in the SNI model of neuropathic pain. Systemic Vit C+E also
ameliorated the allodynia induced by an intrathecal ROS donor.
Antinociceptive effects of intrathecal Vit C+E and a reduced p38
phosphorylation indicate that Vit C+E inhibit neuropathic pain
processing in the spinal cord and DRGs.
Antinociceptive effects of Vit E or Vit C have been reported in
earlier studies. For example, in the streptozotocin (STZ) model of
diabetic neuropathy in rats, very high doses of Vit E (12 g/kg per
day as a dietary supplement for three months) ameliorated nerve
conduction deficits [32], and Vit E at doses of 0.5–1 g/kg per day
for one month improved nerve dysfunction [33]. In a model of
alcohol-induced neuropathic pain, Vit E (0.1 g/kg p.o. per day for
10 weeks) inhibited thermal and mechanical hyperalgesia [27].
Kim et al. [29] observed an attenuation of mechanical allodynia
after a single i.p. dose of Vit E (0.1–5 g/kg) in the spinal nerve
ligation (SNL) model of neuropathic pain in rats. Rosa et al. [34]
reported that a single i.p. dose of Vit C (1–10 mg/kg) may inhibit
both phases of 2.5% formalin-induced paw licking and the
behavioral responses to intrathecal injection of glutamate, NMDA,
AMPA, kainate and substance P in mice, indicating that Vit C
may produce antinociception by interaction with ionotropic
glutamate receptors. Moreover, a recent study revealed that
plasma concentrations of Vit C were lower in patients with
postherpetic neuralgia than in healthy volunteers and that Vit C
treatment decreased spontaneous pain in these patients [35,36],
which is supported by case reports [37,38]. In contrast to the cited
reports, in our study i.p. administration of Vit E or Vit C alone
failed to inhibit the pain behavior in all tested animal models.
About the reasons for these apparently contradictory findings we
can only speculate. One explanation might be that the species and
pain models used in the cited studies were different from those
used in our study. On the other hand, it is likely that that Vit C
and/or Vit E may differentially inhibit some forms of nociceptive
sensory processing or that the vitamins inhibit nociceptive
processing only in specific pain states. In fact, different efficacies
of analgesic drugs across different animal models of pain have
often been reported (for example, see Ref. [39,40]), which further
reflects the complexity of nociceptive processing. Nevertheless,
because the nociceptive tests in our study have been performed
under constant conditions and by the same investigator, our data
demonstrate that Vit C and Vit E may act in a synergistic manner.
To the best of our knowledge, this is the first demonstration that
coadministration of Vit C with Vit E increases the ability of both
vitamins to inhibit pain.
Vit E is an antioxidant that is directly involved in scavenging
ROS and quenching lipid peroxidation chain reactions that occur
during ROS reactions with polyunsaturated fatty acids [41,42].
Vit E reactions result in the formation of tocopheroxyl radicals
that react with other antioxidants to regenerate the active
molecule [43]. Although Vit E is located in membranes and Vit
C is present in aqueous phases, Vit C works to regenerate Vit E
from its radical form, providing an explanation for the synergistic
antioxidative effects if vitamins C and E are given in combination.
Vit C, in turn, can be regenerated from its radical form via the
ascorbate–GSH cycle that uses NADPH generated from the
pentose phosphate pathway as a reducing agent [16]. One has to
consider that nonantioxidant functions of Vit E have long been
reported to contribute to its physiological effects in immune
function, cell signaling, regulation of gene expression and other
metabolic processes [44]. However, more recent data suggest that
most functions of Vit E depend on its antioxidant properties [45].
Our observation that Vit C increases the ability of Vit E to inhibit
the nociceptive behavior further points to an antioxidative process
as the major mechanism underlying the antinociception mediated
by the vitamin combination.
We used relatively high doses of Vit C (15 mg, corresponding to
0.6 g/kg) and Vit E (7.5 mg, corresponding to 0.3 g/kg) in order
Figure 7. Long-term treatment with low dose Vit C and Vit E
inhibits SNI-induced neuropathic pain behavior. Mice were
subjected to SNI surgery and drugs were i.p. (A) or orally (B)
administered at the indicated doses once daily for 12 days starting
immediately after SNI surgery. Paw withdrawal latency times upon
mechanical stimulation are shown. Note that both doses of the Vit C+E
combination inhibited the neuropathic pain behavior after i.p. and oral
administration. n=8 per group; *,
#significantly different from saline
group (p,0.05) for the 3 mg + 1.5 mg combination and the 0.75 mg +
0.375 mg combination, respectively.
doi:10.1371/journal.pone.0029240.g007
Figure 8. Long-term treatment with low dose Vit C and Vit E
does not inhibit CFA-induced inflammatory pain behavior.
Mice were injected with 20 ml CFA into a hindpaw and drugs were i.p.
administered at the indicated doses once daily for 12 days starting
immediately after CFA injection. Paw withdrawal latency times upon
mechanical stimulation are shown. Statistical analyses revealed no
significant differences between groups. n=8 per group.
doi:10.1371/journal.pone.0029240.g008
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nociceptive processing. These doses are certainly too high to be
clinically used in humans, although PK-PD relationships indicate
that differences between efficacious systemic drug exposure levels
in rodents and humans can differ by as much as 50-fold [46].
However, a second i.p. injection of Vit C+E 24 h after the first
injection considerably increased the ability of Vit C+E to inhibit
the neuropathic pain behavior. The most likely reason for this
increased efficacy after repetitive administration is a storage of Vit
E in adipose tissue, leading to cumulative effects [29,47]. These
observations led us to hypothesize that repeated administration of
lower doses of Vit C+E might also exert antinociceptive effects.
Indeed, we show that daily i.p. or oral administration of Vit C
(0.75 mg, corresponding to 30 mg/kg) and Vit E (0.375 mg,
corresponding to 15 mg/kg) attenuate the neuropathic pain
behavior. Considering that metabolic rates differ between mice
and men, it is tempting to speculate that repeated administration
of well-tolerated doses of Vit C+E might also attenuate
neuropathic pain in humans, at least in some cases. In adult
humans, the tolerable upper intake level (i.e., the highest level of
daily nutrient intake that is likely to pose no risk of adverse health
effects in almost all individuals) of Vit E is 1 g per day of any form
of supplementary alpha-tocopherol, whereas the upper intake level
of Vit C is 2 g per day [48]. Notably, intake above the upper
intake level may be appropriate for investigation within well-
controlled clinical trials employing appropriate safety monitoring
of trial subjects [49,50].
We here provide several lines of evidence that spinal
mechanisms contribute to the analgesic effects of Vit C+E. First,
the Vit C+E combination was effective in attenuating neuropathic
pain after intrathecal injection. Second, systemic administration of
Vit C+E attenuated mechanical allodynia induced by intrathecal
TBHP delivery. The reversible nature of the allodynia evoked by
this ROS donor further demonstrates that ROS may exert specific
signaling functions during spinal pain processing [14]. Finally,
systemic administration of Vit C+E reduced phosphorylation of
p38 MAPK in the spinal cord and in DRGs. There is considerable
evidence that the three major members of the MAPK family (p38,
ERK and JNK) play a major role in the maintenance of persistent
pain [30]. In particular, p38, ERK and JNK are differentially
activated in glial cells after peripheral nerve injury, leading to the
synthesis of proinflammatory/pronociceptive mediators, thereby
enhancing and prolonging neuropathic pain. Phospho-p38 begins
to increase in spinal cord microglia at 12 h after nerve injury,
reaches a peak at 3 days, but is maintained at elevated levels even
after 3 weeks [30]. In DRGs, p38 activation occurs predominantly
in neurons [51]. ERK is sequentially activated in microglia (peak
between 1 and 3 days post-surgery) and then in astrocytes (peak 21
days post-surgery) of the dorsal horn, as well as in DRG satellite
cells [52]. Unlike the activation patterns of p38 and ERK, JNK
phosphorylation was primarily observed in spinal astrocytes [53].
Our observation that Vit C+E treatment reduces p38 but not
ERK (p42/p44) phosphorylation in tissue extracts from the spinal
cord and DRGs of SNI-treated animals indicates that p38-
dependent nociceptive signaling in spinal cord microglia and DRG
neurons might be inhibited by the vitamin combination.
Interestingly, a selective activation of p38 by ROS has been
demonstrated in perfused rat hearts [54], and there is evidence
that apoptosis signal-regulating kinase 1 (Ask1), a redox sensitive
MAP3K that activates p38, mediates this effect [55]. However, the
mechanisms by which ROS activate p38 signaling pathways in
nociceptive processing remain to be elucidated.
We also demonstrate that systemic Vit C+E delivery inhibits the
first phase of formalin-induced paw licking. There is much
evidence that this phase is mainly driven by peripheral
mechanisms. Recent studies revealed that formalin at low
concentration (# 0.5%) activates TRPA1, as indicated by a
considerably reduced nociceptive response in TRPA1
2/2 mice
[56,57]. In contrast, the higher concentration (5%) of formalin that
is often used in the formalin test of pain behavior, as we did in our
study, can recruit both TRPA1- and non-TRPA1-expressing
afferents [58]. Interestingly, several key players of nociceptive
transduction have been shown to be redox-modulated. For
example, the capsaicin receptor TRPV1 is potently activated by
endogenous oxidized linoleic acid products, thereby contributing
to inflammatory hyperalgesia [59]. Moreover, redox-based
posttranslational modifications may also alter the function of
TRPA1 channels [60]. It remains to be determined which targets
mediate the antinociceptive effects of Vit C+E during the early
formalin response.
In contrast to the neuropathic pain behavior and the first phase
of formalin-induced paw licking, vitamins C and E failed to affect
the second phase of formalin-induced paw licking and the CFA-
induced inflammatory pain behavior. This finding is somehow
surprising, considering that other studies reported an inhibition of
inflammatory pain behavior after administration of free radical
scavengers or superoxide dismutase mimetics such as phenyl-N-
tert-butylnitrone (PBN), 4-hydroxy-2,2,6,6-tetramethylpiperidine-
1-oxy (TEMPOL), N-acetyl-L-cysteine or M40403 [11–14].
Moreover, the NMDA receptor, which essentially contributes to
nociceptive processing during both inflammatory and neuropathic
pain, is redox regulated with at least seven cysteine residues
involved [61], and its activity can be inhibited by Vit C
administration [34]. These findings implicate that various ROS
effectors exist which are specifically targeted by ROS during the
processing of inflammatory and/or neuropathic pain, and that
different antioxidants may act in a substrate-specific manner.
Moreover, different ROS generators might specifically contribute
to pain processing. Interestingly, recent reports indicate that
members of the NADPH oxidase family, which enzymatically
produce superoxide from oxygen using NADPH as an electron
donor, are expressed at distinct sites of the nociceptive system. For
example, the catalytic NADPH oxidase subunit Nox1 is localized
to DRG neurons, whereas Nox2 is expressed in spinal microglia.
Notably, both subunits have been reported to contribute to
nociceptive processing during persistent pain [8,9]. In other tissues
it has been shown that enzymes including xanthine oxidase and
nitric oxide synthases when ‘‘uncoupled’’ by hypoxia or loss or
oxidation of their cofactor, tetrahydrobiopterin, may also
specifically produce ROS [62]. The relative contributions of
different ROS generators and effectors will need to be worked out,
but ROS are likely to play a prominent role in the sensitization of
pain pathways.
In summary, we here demonstrate that neuropathic pain
induced by peripheral injury and the acute pain response to
formalin can be inhibited by a combination of Vit E and Vit C.
Hence, supplementation or treatment with both vitamins might be
an option in patients suffering from specific pain states.
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